Dishman Pharmaceuticals and Chemicals Limited share price target and research reports

Name: Latest research reports of Dishman Pharmaceuticals and Chemicals Limited authored by BP Wealth and published by - Trendlyne research reports.
Item: Dishman Pharmaceuticals and Chemicals Limited
Rating: 5
Author: BP Wealth

Latest analyst research reports with target prices and PDF download for DISHMAN, BSE:532526 Dishman Pharmaceuticals and Chemicals Limited

Search Inside the pdf :

Dishman Pharmaceuticals and Chemicals Limited

15 Apr 2020

BP Equities Pharmaceuticals Result Preview Q4 FY20

Buy: Dishman Pharmaceuticals an...

Target

BP Wealth

We expect the companies under our pharmaceuticals coverage to report revenue growth of ~6% in Q4FY20 with 14.2% growth in profitability, driven by strong traction in India and API business. The US revenues are expected to decline by 1.6% YoY mainly due to high base and lack of meaningful launches. However, strong ramp-up in gTamiflu and steady base business performance in some US focused players due to potential increase in stocking at the wholesaler level can surprise on the positive side. With respect to domestic markets, the growth is likely to favour companies with larger presence in acute therapy led by extended acute season. Growth in other emerging markets and Europe is likely to be driven by new launches. The recent INR weakness will also benefit Indian pharma companies, but some of the margin benefit is being offset from EM currencies and higher API...

Dishman Pharmaceuticals and Chemicals Limited

25 Jan 2019

Dishman Pharma: Margins and PAT above expectation

Buy: Dishman Pharmaceuticals an...

Target

Karvy

Margins and PAT above expectation: Total Revenues for the quarter grew by 4.2% to Rs 4274 mn, which includesRs 516 mn of other operating income. EBITDA was up by 9.1% YoY to Rs1327 mn on account of better gross margins.

Dishman Pharmaceuticals and Chemicals Limited

18 May 2017

BP Equities Dishman Pharma Ltd Q4FY17 Result Upda

Buy: Dishman Pharmaceuticals an...

BP Wealth

Vitamin D analogues and cholesterol. EBITDA margins expanded from 24.8% to 27.5% (est.27%) on a YoY basis above our estimate mainly due to Carbogen Amcis and Vitamin D business saw upsurge in EBITDA margins.Q4 FY17 PAT decreased by 14% YoY to Rs. 428mn came below our estimate due to Sector Outlook...

Dishman Pharmaceuticals and Chemicals Limited

06 Mar 2017

Result Updates

Sell: Dishman Pharmaceuticals an...

Angel Broking

Dishman Pharmaceuticals posted results lower than expected for 3QFY2017, with sales at Rs356cr v/s. Rs386cr in 3QFY2016, down by 7.6% yoy, mainly on the back of CRAMS. CRAMS sales (Rs246.7cr) de-grew by 16.5% yoy, constituting 69.2% of sales in 3QFY2017; while others (Rs110cr) posted a growth of 21.2% yoy. On the operating front, the gros..

Dishman Pharmaceuticals and Chemicals Limited

15 Feb 2017

BP Equities Dishman Pharma Ltd Q3FY17 Result Upda

Buy: Dishman Pharmaceuticals an...

BP Wealth

logues and cholesterol. EBITDA margins declined from 28.3% in to 26.4% (est.26.7%) on a YoY basis slightly below our estimate mainly due to CRAMS UK and other marketable molecules saw a decline in EBITDA margins.Q3 FY17 PAT increased by 8% YoY to Rs. 547mn came inline with our estimate of Sector Outlook Rs. 547mn due to higher other income (foreign currency gains). Interest expense declined by 27.5% YoY in Q3 FY17 driven by lower debt, conversion of rupee debt into foreign debt. Hence, PAT margin Stock...

Dishman Pharmaceuticals and Chemicals Limited

16 Dec 2016

BP Equities Dishman Pharma Ltd Initiating Coverage

Buy: Dishman Pharmaceuticals an...

BP Wealth

Dishman Pharmaceuticals and Chemicals Limited

30 Nov 2016

Dishman Pharmaceuticals and Chemicals Ltd.

Buy: Dishman Pharmaceuticals an...

Ashika Research

Large Global MNC players prefers CRAMS facility based out of Europe for their research work for any of their molecules starting from phase zero to phase three. Carbogen Amcis contributes 5055% of total revenue and 5-10% growth rate expected from this Share holding pattern as on Sep 2016 (%)...

Dishman Pharmaceuticals and Chemicals Limited

17 Aug 2016

Dishman Pharmaceuticals and Chemicals Ltd

Sell: Dishman Pharmaceuticals an...

Angel Broking

The company posted better than expected results for 1QFY2017 with sales at Rs366cr V/s Rs350cr expected and V/s Rs400cr in 1QFY2016, a yoy de-growth of 8.5%. CRAMS (Rs258cr) posted a growth of 2.3% yoy and the Market Molecules other segment (Rs108cr) posted de-growth of 26.9% yoy. On the operating front, the EBITDA margin came in at 25.3%..

Dishman Pharmaceuticals and Chemicals Limited

05 Aug 2016

Dishman Pharma: Q1FY17 Result Review: Revenues decline, outl... (Aug 05, 2016)

Buy: Dishman Pharmaceuticals an...

Karvy

Revenues for the quarter declined by 8.5% at Rs 3658mn below our estimates of Rs 4181 mn. The margins were at 27.2% in Q1 FY17 as against our estimates of 25.9%. Higher margins were on account of better gross margins and lower other expenses. Profits for the quarter were higher by 11% YoY to Rs 455 mn but lower as against our estimates of Rs 470 mn.

Dishman Pharmaceuticals and Chemicals Limited

30 Jun 2016

Dishman

Buy: Dishman Pharmaceuticals an...

Dynamic Levels

Dishman is a leading global outsourcing partner for the pharmaceutical industry, based in Ahmedabad in Gujarat, India. It has cost-effective, high quality research, development and manufacturing services that include the production and supply of tailormade, high-quality Intermediates and innovative and generic Active Pharmaceutical Ingredients (APIs) straddling the entire pharmaceutical value chain. Dishman is present globally through multiple manufacturing sites in Europe, India, China and Saudi Arabia. Through its end-to-end core...

Is Dishman Pharmaceuticals and Chemicals Limited worth buying?

12 Votes:

Buy 75.0%

Sell 16.67%

Hold 8.33%